Guggenheim Capital LLC increased its position in shares of UiPath Inc. (NYSE:PATH – Get Rating) by 18.8% in the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 63,663 shares of the healthcare company's stock after purchasing an additional 10,062 shares during the period. Guggenheim Capital LLC's holdings in UiPath were worth $803,000 as of its most recent SEC filing.
Several other large investors have also recently added to or reduced their stakes in the company. SeaCrest Wealth Management LLC acquired a new stake in UiPath during the second quarter worth approximately $25,000. Householder Group Estate & Retirement Specialist LLC purchased a new position in shares of UiPath in the 3rd quarter valued at $25,000. Edmond DE Rothschild Holding S.A. purchased a new position in shares of UiPath in the 2nd quarter valued at $59,000. American International Group Inc. purchased a new stake in UiPath during the 2nd quarter worth $74,000. Finally, SRS Capital Advisors Inc. increased its stake in UiPath by 110.0% during the 2nd quarter. SRS Capital Advisors Inc. now owns 4,636 shares of the healthcare company's stock worth $84,000 after buying an additional 2,428 shares during the period. 56.40% of the stock is owned by hedge funds and other institutional investors.
Get UiPath alerts:UiPath Trading Up 1.1 %
Shares of NYSE:PATH opened at $15.44 on Thursday. UiPath Inc. has a fifty-two week low of $10.40 and a fifty-two week high of $31.88. The company's 50-day moving average price is $14.66 and its 200 day moving average price is $13.69.
Insiders Place Their Bets
In other UiPath news, CFO Ashim Gupta sold 40,000 shares of the business's stock in a transaction dated Wednesday, February 15th. The shares were sold at an average price of $16.61, for a total transaction of $664,400.00. Following the sale, the chief financial officer now directly owns 1,359,051 shares in the company, valued at approximately $22,573,837.11. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. 31.88% of the stock is owned by insiders.
Wall Street Analyst Weigh In
PATH has been the topic of several analyst reports. Evercore ISI dropped their price target on shares of UiPath to $17.00 in a research note on Friday, December 2nd. JPMorgan Chase & Co. decreased their price objective on shares of UiPath from $18.00 to $16.00 and set a "neutral" rating for the company in a report on Friday, December 2nd. Barclays decreased their price objective on shares of UiPath from $15.00 to $13.00 and set an "equal weight" rating for the company in a report on Tuesday, January 10th. Truist Financial decreased their price objective on shares of UiPath from $25.00 to $20.00 and set a "buy" rating for the company in a report on Friday, December 2nd. Finally, Royal Bank of Canada decreased their price objective on shares of UiPath from $16.00 to $15.00 and set a "sector perform" rating for the company in a report on Monday, November 28th. Nine equities research analysts have rated the stock with a hold rating and six have given a buy rating to the company. According to data from MarketBeat.com, UiPath currently has an average rating of "Hold" and a consensus price target of $17.97.
UiPath Profile
(Get Rating)
UiPath Inc provides an end-to-end automation platform that offers a range of robotic process automation (RPA) solutions primarily in the United States, Romania, and Japan. The company offers a suite of interrelated software to build, manage, run, engage, measure, and govern automation within the organization.
Further Reading
- Get a free copy of the StockNews.com research report on UiPath (PATH)
- META Platforms May See its Biggest Opening Yet for New Highs
- Penny Stock Vinco Ventures Could Be Big Winner
- Is Chip Design Specialist Synopsys A Gem Hiding In Plain Sight?
- Should You Park Some Capital with Casey's General Stores?
- Crowdstrike Stock: While The Iron Is Hot!
Receive News & Ratings for UiPath Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for UiPath and related companies with MarketBeat.com's FREE daily email newsletter.